CRSP
CRISPR Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
CRSP fundamentals
CRISPR Therapeutics (CRSP) released its earnings on Nov 10, 2025: revenue was 890.00K (YoY +47.84%), missed estimates; EPS was -1.17 (YoY -15.84%), beat estimates.
Revenue / YoY
890.00K
+47.84%
EPS / YoY
-1.17
-15.84%
Report date
Nov 10, 2025
EPS
Revenue
Revenue & Expenses
CRSP has released its 2025 Q3 earnings report, with revenue of 889.00K, reflecting a YoY change of 47.67%, and net profit of -106.44M, showing a YoY change of -23.85%. The Sankey diagram below clearly presents CRSP's revenue sources and cost distribution.
Key Indicators
CRISPR Therapeutics (CRSP) key financial stats and ratios, covering profitability, financial health, and leverage.
CRISPR Therapeutics (CRSP)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
CRISPR Therapeutics (CRSP)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
CRISPR Therapeutics (CRSP)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does CRISPR Therapeutics (CRSP) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track CRISPR Therapeutics (CRSP) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What were the key takeaways from CRISPR Therapeutics's earnings call?What does CRISPR Therapeutics do and what are its main business segments?Did CRISPR Therapeutics beat or miss consensus estimates last quarter?What were the key takeaways from CRISPR Therapeutics’s earnings call?What is CRISPR Therapeutics's latest dividend and current dividend yield?What is the revenue and EPS growth rate for CRISPR Therapeutics year over year?What is the market's earnings forecast for CRISPR Therapeutics next quarter?What factors drove the changes in CRISPR Therapeutics's revenue and profit?
